CStone Pharma-B (02616.HK): CS5007 Global Phase I Trial Initiated, Approved by Australian HREC

Newtimespace (newtimespace.com) reports that CStone Pharmaceuticals (2616.HK) announced that the global multi-center Phase I clinical trial of its Pipeline 2.0 core candidate drug CS5007 (EGFR/HER3 bispecific antibody-drug conjugate [ADC]) has formally received approval from the Australian Human Research Ethics Committee (HREC). This marks the full launch of CS5007's global clinical development.

CS5007 comprises an anti-EGFR/HER3 human IgG1 antibody, CStone's proprietary hydrophilic CSL20 linker, and the clinically validated topoisomerase I inhibitor exatecan. As a bispecific ADC, CS5007 simultaneously targets and blocks both EGFR and HER3 pathways, addressing the common resistance challenges of single-target EGFR therapies. In April 2026, preclinical data presented at the AACR annual meeting further confirmed CS5007's broad-spectrum anti-tumor activity across multiple CDX models including NSCLC, CRC, BC, SCCHN, and SCC, with notable efficacy signals in osimertinib-resistant and EGFR low-expression refractory tumor models.

The initiated global multi-center Phase I trial is a single-agent dose-escalation and expansion study designed to evaluate CS5007's safety, tolerability, preliminary anti-tumor activity, and recommended Phase II dose (RP2D) in advanced solid tumor patients who have progressed after standard therapy, are ineligible for standard treatment, or have no effective treatment options. The study expects to enroll 310 patients and is being conducted simultaneously in Australia and China.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.